Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs Zoetis Inc (ZTS) Price & Performance

MasterCard IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs Zoetis Inc — how do they compare? MasterCard Inc trades at $542.2 (market cap $483.71B), while Zoetis Inc trades at $74.98 (market cap $31.95B). The key difference: MasterCard Inc is far larger — about 15.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.

MAZTS
Market Cap
$483.71B$31.95B
Volume
4,635,698
Sector
Consumer CyclicalHealth
52-Week High
$598.96$156.76
52-Week Low
$471.55$71.91
Enterprise Value
$494.45B$39.24B
Dividend Yield
0.64%2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $541.40, down 0.4% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue growth remains solid, climbing to $32.79 billion in 2025, while maintaining high net income margins above 45%. Recent news highlights Mastercard's AI initiatives in ASEAN and commitment to financial inclusion, targeting 500 million more underbanked individuals by 2030.

The investment outlook is positive, driven by consistent earnings outperformance, expanding profit margins, and a dominant market position. Risks include competitive pressures from emerging payment technologies like stablecoins and elevated valuation multiples. Analyst consensus is strongly bullish with a $634.27 price target, suggesting ~17% upside from current levels. Institutional accumulation continues, though investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.

Zoetis Inc

Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.

The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS